Pharmaceutical News

RSS

Centenary Institute researchers take lead on promising new class of drugs for melanoma treatment

Researchers at Sydney’s Centenary Institute have taken the lead on a promising new class of drugs that may prove to be highly effective for the treatment of certain cases of melanoma.

14 Aug 2015

Opioids produced by yeast; revealing the potential for cheaper pain relief

Researchers at Stanford University have genetically engineered yeast so it produces hydrocodone, a semi-synthetic opioid analgesic used in the United States for relief of moderate to severe pain.

14 Aug 2015

New study focuses on dental screenings for drug misuse

A visit to the dentist has the potential to be more than a checkup of our teeth as patients are increasingly screened for medical conditions like heart disease and diabetes.

14 Aug 2015

PHIV children may lack immunity against measles, mumps, and rubella despite vaccination

Between one-third and one-half of individuals in the United States who were infected with HIV around the time of birth may not have sufficient immunity to ward off measles, mumps, and rubella--even though they may have been vaccinated against these diseases.

14 Aug 2015

CPhI reports positive outlook on the Chinese pharmaceutical market

CPhI – a division of UBM EMEA – alongside UBM Sinexpo, announces the findings of the Pharma Insights China 2015 report.

13 Aug 2015

RealTime Dynamix: New monthly service launched for pharmaceutical markets

Spherix Global Insights announces the launch of RealTime Dynamix, its new monthly service developed to keep clients on the pulse in highly dynamic specialty markets.

13 Aug 2015

Combination of chemotherapy and immune-blocking drug could prevent cancer recurrence

Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people, according to research published today in Cancer Research.

13 Aug 2015

BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

BioDelivery Sciences International, Inc. announced the approval by the U.S. Food and Drug Administration of a Supplemental New Drug Application (sNDA) for a new formulation of ONSOLIS (fentanyl buccal soluble film) CII for the management of breakthrough pain in patients with cancer who are opioid tolerant.

13 Aug 2015

New study explains why statins are more beneficial than others in some cases

Statins' success in reducing atherosclerosis-related events has elevated the medications to wonder-drug status, with some researchers advocating for their wider use as a preemptive therapy for cardiovascular disease.

13 Aug 2015

Increasing vaccination coverage in the US protects against chickenpox

Since the chickenpox vaccine became available in the U.S. in 1995, there has been a large reduction in chickenpox cases. Hospitalizations and outpatient visits for chickenpox have continued their decline after a second dose of the vaccine was recommended to improve protection against the disease, according to a new study published in the Journal of the Pediatric Infectious Diseases Society.

13 Aug 2015

Abortions performed with Mifepristone result in shorter waiting time, earlier abortions

Nearly all abortions in Norway today are performed with the abortion pill Mifepristone. This has resulted in shorter waiting time, earlier abortions, and the possibility to have abortions at home.

13 Aug 2015

CrystalGenomics signs agreement with Dong-A ST for commercialization of Acelex (polmacoxib) in Korea

CrystalGenomics, Inc. has announced that it has signed a Sales and Marketing Agreement with Dong-A ST Co., Ltd. for the commercialization of Acelex (polmacoxib) in Korea.

13 Aug 2015

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.

12 Aug 2015

Postmenopausal women more likely to use vaginal estrogen to achieve significantly higher sexual quality of life

Local vaginal estrogen (VE) appears to have escaped the shroud of doubt cast upon hormone therapy as a result of the Women's Health Initiative Study by providing numerous medical benefits without systemic effects. That's according to a new study reported online today in Menopause, the journal of The North American Menopause Society.

12 Aug 2015

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.

12 Aug 2015

Findings may lead to more accurate diagnostic test, possible vaccine for oral and genital herpes

Findings from a pair of new studies could speed up the development of a universally accurate diagnostic test for human herpes simplex viruses, according to researchers at Johns Hopkins and Harvard universities and the National Institutes of Health.

12 Aug 2015

Study finds no added benefit for insulin degludec and liraglutide in type 2 diabetes

The fixed-ratio combination of the two drugs insulin degludec and liraglutide (trade name: Xultophy) has been approved since September 2014 for adults with type 2 diabetes mellitus. It is given as an injection in addition to other blood-glucose lowering drugs when these alone or in combination with basal insulin are insufficient to lower blood glucose levels.

12 Aug 2015

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Janssen Biotech, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson announced today an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies.

12 Aug 2015

IQWiG dossier assessment finds no added benefit for vortioxetine in depression

Vortioxetine (trade name: Brintellix) has been approved since December 2013 for the treatment of depression in adults, but did not become actually available before May 2015. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier because it contained no data evaluable for the assessment.

12 Aug 2015

Novel combination therapy effective at treating patients with skin metastases

In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown.

12 Aug 2015

Pharmaceutical News

Centenary Institute researchers take lead on promising new class of drugs for melanoma treatment

Opioids produced by yeast; revealing the potential for cheaper pain relief

New study focuses on dental screenings for drug misuse

PHIV children may lack immunity against measles, mumps, and rubella despite vaccination

CPhI reports positive outlook on the Chinese pharmaceutical market

RealTime Dynamix: New monthly service launched for pharmaceutical markets

Combination of chemotherapy and immune-blocking drug could prevent cancer recurrence

BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

New study explains why statins are more beneficial than others in some cases

Increasing vaccination coverage in the US protects against chickenpox

Abortions performed with Mifepristone result in shorter waiting time, earlier abortions

CrystalGenomics signs agreement with Dong-A ST for commercialization of Acelex (polmacoxib) in Korea

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

Postmenopausal women more likely to use vaginal estrogen to achieve significantly higher sexual quality of life

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Findings may lead to more accurate diagnostic test, possible vaccine for oral and genital herpes

Study finds no added benefit for insulin degludec and liraglutide in type 2 diabetes

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

IQWiG dossier assessment finds no added benefit for vortioxetine in depression

Novel combination therapy effective at treating patients with skin metastases

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News